Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Red de investigación Renal

IP: Daniel Serón Micas
Collaborators: Joan López Hellin, Anna Meseguer Navarro, Francesc Moreso Mateos, Enric Trilla Herrera, Natalia Ramos Terrades, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá, Manel Perelló Carrascosa
Funding agency: Instituto de Salud Carlos III
Funding: 92250
Reference: RD12/0021/0013
Duration: 01/01/2013 - 31/12/2016

Kidney and sex hormones: Novel insights into development and progression of the metabolic syndrome

IP: Anna Meseguer Navarro
Collaborators: Joan López Hellin, Concepció Jacobs Cachá, Andrea Caballero Garralda
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 266200
Reference: SAF2011-29506
Duration: 01/01/2012 - 31/12/2014

Ministerio de Ciencia

Acción andrógénica y función renal: Implicación de la Kidney androgen-regulated protein (KAP)

IP: Anna Meseguer Navarro
Collaborators: Joan López Hellin, Maria Teresa Salcedo Allende, Thais Cuadros Arasa, Concepció Jacobs Cachá
Funding agency: Sociedad Española de Nefrología (S.E.N.)
Funding: 18000
Reference: SENEFRO/01/08
Duration: 01/02/2009 - 31/01/2011

Patologia Cel·lular

IP: Anna Meseguer Navarro
Collaborators: Joan López Hellin, Ramón Vilalta Casas, Alvaro Domingo Madrid Aris, Francesc Moreso Mateos, Enric Trilla Herrera, Daniel Serón Micas, Luis Enrique Lara Moctezuma, Thais Cuadros Arasa, Concepció Jacobs Cachá, Carles Xavier Raventós Busquets
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2009 SGR 75
Duration: 01/01/2010 - 30/04/2014

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Cristina  Valles  Valles

Cristina Valles Valles

Childhood Cancer and Blood Disorders
Read more
Marta Miarons Font

Marta Miarons Font

Head of group
Basic, Translational and Clinical Pharmacy Research
Read more
Alvaro Garcia Tornel Garcia Camba

Alvaro Garcia Tornel Garcia Camba

Senior researcher
Stroke research
Read more
Ferran Polo Torres

Ferran Polo Torres

Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.